



INNOVATIONS IN COVID-19

Bridging opportunities
at Oswaldo Cruz Institute

VASCULOPATHY AND GRAVITY IN COVID-19 EXPERIMENTAL AND THE ROLE OF ACE2

(COD. 2020.016)

COORDINATOR

Leonardo Jose de Moura Carvalho

RESEARCH AREA

New Drugs

DEVELOPMENT STAGE

Level 1 - TRL - Basic principles observed and reported. MRL - Basic principles observed and reported.

PROPOSITION / APPLICATION

Covid-19 can progress with generalized vasculitis, leading to serious complications such as ischemia, coagulopathy, thrombosis, cardiac arrest and stroke. The SARS-CoV-2 virus interacts with key molecules of the vascular system, inducing a vasoconstrictor, pro-inflammatory and pro-coagulant environment.

INNOVATION

The project is innovative in assessing how therapies with antihypertensive drugs affect the Covid-19 outcome, proposing new therapeutic practices, particularly in patients with cardiovascular diseases.

OPPORTUNITY

Evaluation of possible therapies for clinical trials.

CONTACT

nit@ioc.fiocruz.br